Collectively, these results indicate that ITGB4 may play a critical role in regulating gemcitabine sensitivity in cholangiocarcinoma cells, and its silencing enhances the antiproliferative and pro-apoptotic effects of gemcitabine. The gene discussed is ITGB4; the disease is cholangiocarcinoma.